OPHI CollPlant Biotechnologies Ltd
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 1631487 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY360.4%
TTM net income YoY30.8%
TTM EPS YoY35.2%
Revenue 3-yr CAGR99.4%
Net income 3-yr CAGR—
Margins
Gross margin64.8%
Operating margin-484.3%
Net margin-484.6%
FCF margin-398.4%
EBITDA margin-445.8%
Returns
ROE-117.6%
ROA-77.9%
ROIC (approx.)-886.8%
Asset turnover0.16x
Leverage & solvency
Liabilities / assets43.6%
Debt / equity0.00x
Current ratio2.53x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-14.0%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.37M | $515,000 |
| Cost of revenue | $835,000 | $1.62M |
| Gross profit | $1.54M | -$1.11M |
| R&D expense | $8.19M | $10.52M |
| SG&A expense | $4.83M | $5.63M |
| Operating income | -$11.48M | -$17.25M |
| Income tax | — | $45.99M |
| Net income | -$11.49M | -$16.61M |
| EBITDA | -$10.57M | -$16.21M |
| EPS (basic) | -0.94 | -1.45 |
| EPS (diluted) | -0.94 | -1.45 |
| Weighted avg. shares (diluted) | 12.20M | 11.45M |
| Balance sheet | ||
| Cash & equivalents | $5.59M | $11.91M |
| Receivables | $1,000 | $150,000 |
| Inventory | $573,000 | $440,000 |
| Current assets | $6.75M | $13.18M |
| PP&E, net | $1.46M | $2.29M |
| Intangibles | $73,000 | $131,000 |
| Total assets | $10.79M | $18.71M |
| Current liabilities | $2.67M | $2.97M |
| Total liabilities | $4.70M | $5.25M |
| Shareholders' equity | $6.08M | $13.46M |
| Shares outstanding | 12.80M | 11.45M |
| Cash flow statement | ||
| Operating cash flow | -$9.42M | -$14.09M |
| Capital expenditure | $28,000 | $483,000 |
| Free cash flow | -$9.45M | -$14.58M |
| Investing cash flow | -$27,000 | -$539,000 |
| Financing cash flow | $3.10M | $9,000 |
| Depreciation & amortization | $912,000 | $1.04M |
| Stock-based compensation | $999,000 | $1.72M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.